Questions? Comments? Send us a message!

As we move from the NCHPP website to our new home, we're porting our most popular series: The ACHPN prep course. It's free and may help you with enough questions to pass the darned thing. It's a very poorly written exam, so get all the help you can! You can do it!

Support the show

Thank you for your interest in Ethics in Palliative Medicine! Follow us at https://epionepalliative.com and on X: @PallCareEthics

Questions? Comments? Send us a message!

In this episode we discuss suzetrigine, a novel, non-opioid pain medication that specifically targets the NaV1.8 sodium channel to manage acute pain. The document explores its pharmacological mechanisms, highlighting how it blocks pain signals without causing the addictive or severe side effects associated with traditional opioids like respiratory depression or sedation. It reviews preclinical findings and clinical trial results, showcasing suzetrigine’s effectiveness in reducing postoperative pain with a favorable safety profile. The manuscript concludes by discussing suzetrigine’s potential to address the opioid crisis by providing a safer alternative for pain management, while also emphasizing the need for further research into its long-term applications.

Support the show

Thank you for your interest in Ethics in Palliative Medicine! Follow us at https://epionepalliative.com and on X: @PallCareEthics

Questions? Comments? Send us a message!

This episode examines Hypertrophic Pulmonary Osteoarthropathy (HPO), a rare syndrome often associated with underlying pulmonary malignancies. It outlines HPO's clinical presentation, which includes digital clubbing and painful, swollen joints, emphasizing the importance of differentiating it from metastatic bone pain due to its bilateral and symmetrical nature on bone scans. The text further explores the proposed pathophysiological mechanisms, particularly the roles of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Finally, it discusses treatment strategies, highlighting that addressing the underlying disease is most effective, but also suggesting symptomatic relief options such as bisphosphonates, octreotide, and anti-inflammatory drugs for patients not amenable to primary disease treatment.

Support the show

Thank you for your interest in Ethics in Palliative Medicine! Follow us at https://epionepalliative.com and on X: @PallCareEthics